We strive to provide individuals with disabilities equal access to our website. If you would like information about this content we will be happy to work with you. Please email us at: McKinsey_Website_Accessibility@mckinsey.com
Many diseases today don’t have a cure. One reason is that drug discovery is difficult: finding and developing an effective medicine is a yearslong and very expensive process. But maybe it doesn’t have to be. Experts say AI—if properly integrated into scientists’ research—could revolutionize drug discovery, making it possible for more patients to get the treatments they need.

The view to 2030

‘We will have life-changing, game-changing drugs ... getting to the right patient at the right time’

Hear three of McKinsey’s life-sciences experts describe the potentially transformative effects of AI, data, and analytics on the process of drug discovery. Alex Devereson, Christoph Sandler, and Lydia The envision a world in which scientists will be able to automate previously manual tasks and generate new insights at an unprecedented pace. But, for that to happen, companies will need to radically change the way they work.

 

We strive to provide individuals with disabilities equal access to our website. If you would like information about this content we will be happy to work with you. Please email us at: McKinsey_Website_Accessibility@mckinsey.com

More on the future of biotech

Article

AI in biopharma research: A time to focus and scale

– By focusing on specific scientific and operational pain points and fully integrating AI into research workflows, biopharma companies... can deliver greater patient impact and significant value.
Article

Self-learning: The dawn of a new biomedical R&D paradigm

– Science and technology are driving breakthroughs at each stage of the biomedical R&D value chain. Enhancing feedback loops... among them could unleash a self-learning model that would benefit patients.
Article

What are the biotech investment themes that will shape the industry?

– From 2019 to 2021, venture capitalists plowed $35 billion into biotech companies with advanced platform technologies that could... transform the industry.
Article

Transforming biopharma R&D at scale

– Transformations often struggle to scale up and make change stick. To achieve lasting impact, high-performing R&D organizations... pay heed to the five outcomes that matter most.
Article

Better data for better therapies: The case for building health data platforms

– Health data platforms that participants trust could bring an end to today’s reductionist approach to drug development, revolutionizing... our understanding of disease.
Article

Generating real-world evidence at scale using advanced analytics

– As pharma companies apply advanced analytics to generate new types of evidence, how do they decide which use cases to target and... how to scale them up across the business?
Article

Ten battlegrounds for digital and analytics in life sciences

– Life-sciences companies have yet to realize the full potential of digital and analytics. Pioneers are finding success by focusing... on entire parts of the business system rather than use case projects.
Article

Creating value from next-generation real-world evidence

– Leading pharma companies are applying advanced analytics to real-world evidence generation to deliver impact at scale. How can... leaders keep innovating, and what should others do to catch up?

In upcoming editions, The Next Normal will explore the future of grocery, college, travel, and more.

Become future-ready. Get every edition of The Next Normal in your inbox.

Latest editions of The Next Normal